Teladoc Health, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2024
For the Full year, the company expects revenue of $2,635 million to $2,735 million, net loss per share of $1,10 to $0.80.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.73 USD | -1.32% | +4.00% | -40.93% |
Apr. 29 | Truist Securities Cuts Teladoc's Price Target to $15 From $17, Maintains Hold Rating | MT |
Apr. 26 | UBS Adjusts Teladoc Price Target to $16 From $20, Maintains Neutral Rating | MT |
1st Jan change | Capi. | |
---|---|---|
-40.93% | 2.19B | |
+63.71% | 3.02B | |
+115.18% | 703M | |
+8.27% | 475M | |
-67.19% | 144M | |
-32.23% | 85.14M |